CDK4/6抑制剂治疗与角膜上皮改变相关
这项回顾性横断面研究纳入132名女性,比较CDK4/6抑制剂联合芳香化酶抑制剂(CDKAI组)、芳香化酶抑制剂单药(AI组)与无全身肿瘤治疗对照组的角膜上皮改变。CDKAI组点状上皮病变(PE)患病率为44.4%,显著高于AI组的4.7%和对照组的2.3%;涡状角膜病变仅见于CDKAI组(13.3%),且泪膜功能指标组间无差异。
要点
- CDKAI组PE患病率44.4%,明显高于AI组4.7%和对照组2.3%。
- 所有中度和重度/复杂PE病例均仅出现在CDKAI组。
- 涡状角膜病变仅见于CDKAI组(13.3%),泪膜指标组间无差异。
核心结论
- CDK4/6抑制剂治疗与PE和涡状角膜病变的患病率及严重程度显著升高相关,且不依赖芳香化酶抑制剂暴露,也未伴随可测量的泪膜功能障碍。
- 上述结果提示CDK4/6抑制剂对角膜上皮可能存在直接的细胞抑制作用。
- CDK4/6抑制剂治疗期间或有必要主动进行角膜表面评估,包括荧光素染色。
研究设计与样本
- 回顾性比较性横断面研究,在三级眼科中心开展。
- 共纳入132名女性:CDKAI组45例,AI组44例,年龄匹配的无全身肿瘤治疗绝经后对照组43例。
- 暴露为CDK4/6抑制剂(ribociclib、palbociclib或abemaciclib)联合芳香化酶抑制剂、芳香化酶抑制剂单药或无全身肿瘤治疗。
- 主要结局为PE和涡状角膜病变的患病率与严重程度,由设盲眼科医生评估。
主要发现
- CDKAI组PE患病率为44.4%,AI组为4.7%,对照组为2.3%(χ² = 34.31;P < .001)。
- 所有中度(13.3%)和重度/复杂(8.9%)PE病例均仅出现在CDKAI组。
- 涡状角膜病变见于13.3%的CDKAI患者,其他组均无(P = .025)。
- Schirmer值、泪膜破裂时间和OSDI评分组间均无差异(所有P > .05)。
- CDKAI组内,PE与治疗持续时间(P = .963)或泪膜参数无关。
关键数值与推荐
- PE患病率:CDKAI组44.4%、AI组4.7%、对照组2.3%(χ² = 34.31;P < .001)。
- 涡状角膜病变:CDKAI组13.3%,其他组0%(P = .025)。
- 中度PE占13.3%、重度/复杂PE占8.9%,均仅见于CDKAI组。
- 泪膜功能指标组间比较均P > .05。
临床怎么用
- 对接受CDK4/6抑制剂联合芳香化酶抑制剂的患者,可考虑主动进行角膜表面评估并行荧光素染色。
- 即使泪膜功能指标正常,也应注意CDK4/6抑制剂相关角膜上皮改变的可能。
- 症状评分较低,但OSDI解读受回答不完整限制,不应仅凭症状判断角膜上皮状态。
局限性
- 为回顾性比较性横断面研究,不能确立因果关系。
- OSDI解读受回答不完整限制。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are standard therapy for hormone receptor-positive (HR+), HER2-negative breast cancer. By blocking the G1/S cell-cycle transition, these agents may impair renewal of the corneal epithelium. No controlled study has systematically evaluated corneal epithelial changes in patients receiving CDK4/6 inhibitors. OBJECTIVE: To determine whether CDK4/6 inhibitor-based therapy is associated with cornealepithelial alterations independent of aromatase inhibitor exposure and tear film dysfunction. DESIGN, SETTING, AND PARTICIPANTS: Retrospective comparative cross-sectional study at a tertiary ophthalmology center. A total of 132 women were enrolled: 45 receiving a CDK4/6 inhibitor plus an aromatase inhibitor (CDKAI group), 44 receiving aromatase inhibitor monotherapy (AI group), and 43 age-matched postmenopausal controls without systemic oncologic therapy. EXPOSURES: CDK4/6 inhibitor (ribociclib, palbociclib, or abemaciclib) combined with an aromatase inhibitor; aromatase inhibitor alone; or no systemic oncologic therapy. MAIN OUTCOMES AND MEASURES: Prevalence and severity of punctate epitheliopathy and vortex keratopathy, assessed by a masked ophthalmologist. Secondary outcomes included Schirmer I test, tear film break-up time, and Ocular Surface Disease Index (OSDI). RESULTS: PE was present in 44.4% of eyes in the CDKAI group vs 4.7% in the AI group and 2.3% in controls (χ² = 34.31; P < .001). All moderate (13.3%) and severe/complicated (8.9%) PE cases occurred exclusively in the CDKAI group. Vortex keratopathy was observed in 13.3% of CDKAI patients and in none of the other groups (P = .025). Schirmer values, tear film break-up time, and OSDI scores did not differ among groups (all P > .05). Within the CDKAI group, PE was not associated with treatment duration (P = .963) or tear film parameters. CONCLUSIONS AND RELEVANCE: In this comparative study, CDK4/6 inhibitor-based therapy was associated with significantly higher prevalence and severity of PE and vortex keratopathy, independent of aromatase inhibitor exposure and in the absence of measurable tear film dysfunction. These findings suggest a direct cytostatic effect on the corneal epithelium. Symptom scores were low, although OSDI interpretation was limited by incomplete responses. Proactive corneal surface evaluation with fluorescein staining may be warranted during CDK4/6 inhibitor treatment.
引用
- Ozbay EK, Ozturk B, Ozbay MF, et al. Corneal Epithelial Alterations Associated With Cyclin-Dependent Kinase 4/6 Inhibitor Therapy in Hormone Receptor-Positive Breast Cancer. Am J Ophthalmol. 2026. PMID: 42341974. doi:10.1016/j.ajo.2026.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。